[1] Stanaway JD, Flaxman AD, Naghavi M, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet 2016, 388:1081-1088.
[2] Sarin SK, Kumar M, Eslam M, et al. Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology&Hepatology Commission. Lancet Gastroenterol Hepatol, 2020, 5:167-228.
[3] Fattovich G. Natural history of hepatitis B. J Hepatol, 2003, 39 Suppl 1:S50-S58.
[4] Lampertico P, Agarwal K, Berg T, et al. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol, 2017, 67:370-398.
[5] Omata M, Cheng A, Kokudo N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int, 2017, 11:317-370.
[6] Hou JL, Zhao W, Lee C, et al. Outcomes of long-term treatment of chronic HBV infection with Entecavir or other agents from a randomized trial in 24 countries. Clin Gastroenterol Hepatol, 2020, 18:457-467.
[7] Zhang YQ, Peng LJ, Cao YR, et al. Risk factors for hepatocellular carcinoma in cirrhotic patients with chronic hepatitis B. Genet Test Mol Biomarkers, 2016, 20:535-543.
[8] Yan H, Zhong G, Xu G, et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife, 2012, 1. e00049.
[9] Allweiss L, Dandri M. The role of cccDNA in HBV Maintenance. Viruses, 2017, 9:1-12.
[10] Tu T, Budzinska MA, Shackel NA, et al. Conceptual models for the initiation of hepatitis B virus-associated hepatocellular carcinoma. Liver Int, 2015, 35:1786-1800.
[11] 张原青,郭津生. 乙型肝炎病毒促进肝细胞性肝癌发生的机制. 中华肝脏病杂志,2016, 24:152-156.
[12] Yip TC, Wong GL. Current knowledge of occult hepatitis B infection. Semin Liver Dis, 2019,39:249-260.
[13] Garcia-Tsao G, Friedman S, Iredale J, et al. Now there are many (stages) where before there was one: In search of a pathophysiological classification of cirrhosis. Hepatology, 2010, 51:1445-1449.
[14] Liang TJ. Hepatitis B: the virus and disease. Hepatology,2009,49: S13-S21.
[15] Cui Y, Jia J. Update on epidemiology of hepatitis B and C in China. J Gastroenterol Hepatol, 2013, 28:7-10.
[16] Li J, Bao M, Ge J, et al. Research progress of therapeutic vaccines for treating chronic hepatitis B. Hum Vaccin Immunother, 2017,13:986-997.
[17] Lampertico P, Invernizzi F, Vigano M, et al. The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: a 12-year prospective cohort study. J Hepatol, 2015, 63:1118-1125.
[18] Jang JW, Choi JY, Kim YS, et al. Long-term effect of antiviral therapy on disease course after decompensation in patients with hepatitis B virus-related cirrhosis. Hepatology, 2015, 61:1809-1820.
[19] Terrault NA, Bzowej NH, Chang KM, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology, 2016, 63:261-283.
[20] Huang DQ, Lim SG. Hepatitis B: who to treat? a critical review of intermational guidelines. Liver Int, 2020,40(Suppl 1):5-14.
[21] Papatheodoridis G, Vlachogiannakos I, Cholongitas E, et al. Discontinuation of oral antivirals in chronic hepatitis B: A systematic review. Hepatology, 2016, 63:1481-1492.
[22] Cornberg M, Lok AS, Terrault NA, et al. Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. J Hepatol, 2020, 72:539-557.
[23] Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int, 2016, 10:1-98.
[24] 王贵强,王福生,庄辉等. 慢性乙型肝炎防治指南(2019年版) . 中华肝脏病杂志,2019, 27:938-961.
[25] Zhang S, Wang F, Zhang Z. Current advances in the elimination of hepatitis B in China by 2030. Front Med, 2017, 11:490-501.
[26] Liu J, Yang HI, Lee MH, et al. Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma. Gut, 2014, 63:1648-1657.
[27] Loomba R, Liang TJ. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions. Gastroenterology, 2017, 152:1297-1309.
[28] Hwang JP, Lok AS. Management of patients with hepatitis B who require immunosuppressive therapy. Nat Rev Gastroenterol Hepatol, 2014, 11:209-219.
[29] Lim YS. Management of antiviral resistance in chronic hepatitis B. Gut Liver, 2017, 11:189-195.
[30] Tseng TC, Kao JH. Elimination of hepatitis B: is it a mission possible? BMC Med, 2017, 15:53.
[31] Gane EJ. Future anti-HBV strategies. Liver Int, 2017, 37:40-44.
[32] Dusheiko G. Will we need novel combinations to cure HBV infection? Liver Int, 2020, 40: 35-42.
[33] 刘珏,刘民. 我国实现WHO 2030消除乙型肝炎目标的进展与挑战. 中华流行病学杂志, 2019, 40: 605-609. |
